Snigdha Srivastava

Ms. Snigdha Srivastava

Dr. A.P.J. Abdul Kalam Technical University, Lucknow, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2023 in INTERNATIONAL JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH (IJPER)
Verified
Journal Article
Open access
PDF file
SSSnigdha Srivastava
Snigdha Srivastava
RSReema Sinha
Reema Sinha
PLPallavi M. Lavhale
Pallavi M. Lavhale
RKRajan K. Kurmi
Rajan K. Kurmi
For the almost 500 decades, naturally occurring plant products always showed a narrative role to society for their effectiveness against several diseases. Carvone is a mono-terpenoid which is obtained as an essential oil obtained from Anethum graveolens (dill) and Carum carvi (caraway) oils, S(+) enantiomer and the (-R) enantiomer of carvone as a primary constituent of Mentha spicata (spearmint) oil also found in Calamintha officinalis (calamint) oil. As Carvone has shown a very less toxic effect. S(+) Carvone also acts as an anti-epileptic agent, (S &R) Carvone has shown much more potent activity when compared to (R) species of carvone. By performing In-silico docking studies of S(+) Carvone it has been observed that it is quite safe and potentially effective as an anticonvulsant agent, antispasmodic agent, antifungal agent, also as a cardiovascular agent etc. Carvone has a high permeability to GI absorption and also it follows the Lipinski rule (0 violations). Although, Carvone has less toxicity while crossing the blood-brain barrier. Docking studies of carvone is suggesting that it can be used for many advancements of the drug to achieve potent results in different pharmacological aspects.

26 March 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
RKRAJAN KUMAR Kurmi
RAJAN KUMAR Kurmi
SSSnigdha Srivastava
Snigdha Srivastava
DSDr. Reema Sinha
Dr. Reema Sinha
The main inhibitory neurotransmitter in the mammalian brain is 4-aminobutyric acid (GABA). Phthalimide acts as a sodium channel antagonist, one of the finest targets for treating epilepsy is the sodium channel and JNK kinase activity is inhibited to treat epilepsy. a novel compound with multiple targets of action for the treatment of epilepsy also anti-oxidant activity has been designed. The compounds are designed in two series aldehydes and aniline. Docking of all the designed compounds has been done with the suitable protein GABA-AT, sodium channel, JNK protein, and anti-oxidant from protein bank. QSAR was done for constructing many linear regression models. In combination with the developed Docking and QSAR outcomes, ADMET has been performed for the active compounds. The result shows that 11 of the compounds have excellent binding energy in docking with all the receptors and also have good QSAR results and follow the ADMET. The structural understanding of human GABA-AT inhibition was obtained from molecular dynamics simulation studies for compound no. 11 at 5 nanoseconds. Synthesis and pharmacological activity also suggest that the designed compound no.11 be considered the best Novel Compound.

22 January 2026 in Bulletin of the National Research Centre
Verified
Journal Article
Open access
PDF file
RKRAJAN KUMAR Kurmi
RAJAN KUMAR Kurmi
SSSnigdha Srivastava
Snigdha Srivastava
VSVikas Sharma
Vikas Sharma
Single-atom catalysts (SACs) have emerged as a powerful class of nano-catalysts for tumor therapy due to their well-defined active sites and exceptional ca

30 January 2026 in Nutrire
Verified
Journal Article
Open access
PDF file
NSNiti Sharma
Niti Sharma
PYPreeti Yadav
Preeti Yadav
SSSanket Sharma
Sanket Sharma
SSSnigdha Srivastava
Snigdha Srivastava
RKRAJAN KUMAR Kurmi
RAJAN KUMAR Kurmi
TYTanu Yadav
Tanu Yadav
Chronic kidney disease (CKD) is a prevalent and complex disorder in the current clinical landscape. Adequate intake of essential micronutrients is required